French
A family story. Founded in 1929 by a husband and wife team of pharmacists, Mayoly Spindler was bought in 1975 by Dr Jean Marie Vernin.
The following years were punctuated by numerous product launches and events that can be grouped into three major periods:
From 1975 to 1982, with the launch of Charlieu shampoos and the handover of the company by Jean-Marie Vernin to his son Jean-Gilles Vernin.
From 1982 to 2008, with the acquisition of Laboratoires Galéniques Vernin, Rosa-Phytopharma and Opocalcium and in 1994 the launch of the Topicrem range, quickly followed by the acquisitions and launches of the products Helikit, Eurobiol, Colchicine and Colchimax.
From 2008 to today, with the handover of the company from Jean-Gilles Vernin to his son Jean-Nicolas Vernin and the product launches of Colokit, Cholurso, Mikicort and Probiolog Strong, and the acquisition of the dermatological product line of Laboratoires Thea. 2014 was marked by the arrival of Stéphane Thiroloix as Managing Director. Recent events also include additions to the Topicrem line and OTC product launches.
Mayoly Spindler is still an entirely family-owned, French independent laboratory.
Independent
Proud to be independent
Our status as a proudly independent lab is our main performance driver. We demand operational excellence in order to preserve our ability to finance our investments and geographic expansion. Pride in our independence is shared by everyone in the organization and influences how decisions are made. We manage the company with a vision than spans generations, not just a month or a year. This long-term vision allows us to focus on stable and steady plans for enduring growth.
International
An international focus is now firmly part of the corporate culture.
The successes in France naturally encouraged Mayoly Spindler to pursue global ambitions. To conquer international markets, the company began by entering into distribution agreements with local agents. Throughout the last twenty years, we have established partnerships in many countries, and in some cases we opened subsidiaries in order to ramp up our product development business.
Founded in 1970, the Belgian subsidiary was our first subsidiary. The expansion continued in 2005 with the creation of the Mexican subsidiary to reach the North American market.
In 2011, Mayoly Spindler opened subsidiaries in Russia and Algeria, followed by Spain in 2014 and England in 2016. Supported by a desire to develop high-performance products for specific therapeutic applications, Mayoly Spindler now earns 41% of its revenue in international markets.